Paper 65 - PRE-TREATMENT CTDNA BURDEN AND GENOMIC FEATURES ARE PROGNOSTIC AMONG PATIENTS WITH METASTATIC EWING SARCOMA TREATED ON AEWS1221: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP (COG)

Saturday, November 4, 2023

10:00 AM – 11:00 AM

Author(s)

David S. Shulman, MD

Instructor
Dana-Farber/Boston Children's Cancer and Blood Disorders Center
Boston, Massachusetts, United States

Slides

Co-Author(s)

KK

Kelly Klega, MS, MLS(ASCP)

Dana-Farber Cancer Institute
Boston, Massachusetts, United States
AB

Allen B. Buxton, MS (he/him/his)

Statistician
Public Health Institute, Children's Oncology Group
Monrovia, California, United States
MT

Mohammad Tanhaemami, MS

Bioinformatics Analyst
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
VB

Victoria Bainer, n/a

Dana-Farber Cancer Institute
Boston, Massachusetts, United States
CC

Carrie Cibulskis, n/a

The Broad Institute
Boston, Massachusetts, United States
RG

Richard Gorlick, MD

Professor
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Julia L. Glade Bender, MD (she/her/hers)

Member and Vice Chair for Clinical Research
Memorial Sloan Kettering Cancer Center
New York, New York, United States
DR

Damon Reed, MD

Moffitt Cancer Center
Tampa, Florida, United States
KJ

Katherine A. Janeway, MD

Dana-Farber/Boston Children's Cancer and Blood Disorders Center
Boston, Massachusetts, United States
MK

Mark Krailo, PhD

Professor
University of Southern California
Los Angeles, California, United States
SD

Steven G. Dubois, MD, MS

Associate Professor
Dana-Farber/Boston Children’s Cancer and Blood Disorders Center
Boston, Massachusetts, United States
Brian D. Crompton, MD

Co-Director for Research, Pediatric Solid Tumor Program Assistant Professor of Pediatrics, Harvard Medical School Associate Member, Broad Institute of Harvard and MIT Dana-Farber/Boston Children’s Cancer and Blood Disorders Center
Dana-Farber/Boston Children's Cancer and Blood Disorders Center
Boston, Massachusetts, United States